by Brigham and Women’s Hospital Credit: Pixabay/CC0 Public Domain Preliminary results from a landmark clinical trial to prevent Alzheimer’s disease (AD) symptoms show that an investigational anti-amyloid drug, solanezumab, did not demonstrate a statistically significant slowing of cognitive decline associated with AD when initiated prior to the stage of clinical impairment. The Anti-Amyloid Treatment in...